Literature DB >> 20927320

Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions.

Kathrine Røe1, Therese Seierstad, Alexandr Kristian, Lars Tore Gyland Mikalsen, Gunhild Mari Mælandsmo, Albert J van der Kogel, Anne Hansen Ree, Dag Rune Olsen.   

Abstract

Prostate cancer (PCa) patients receive androgen-deprivation therapy (ADT) to reduce tumor burden. However, complete eradication of PCa is unusual, and recurrent disease is evident within approximately 2 years in high-risk patients. Clinical evidence suggests that combining ADT with radiotherapy improves local control and disease-free survival in these patients compared with radiotherapy alone. We investigated whether vascularization of androgen-sensitive PCa xenografts changed after ADT and whether such therapy affected radiation response. CWR22 xenografts received combinations of ADT by castration (CWR22-cas) and 15 Gy of single-dose irradiation. At a shortest tumor diameter of 8 mm, vascularization was visualized by dynamic contrast-enhanced magnetic resonance imaging before radiation and 1 and 9 days after radiation. Voxel-wise quantitative modeling of contrast enhancement curves extracted the hemodynamic parameter K(trans), reflecting a combination of permeability, density, and blood flow. Tumor volumes and prostate-specific antigen (PSA) were monitored during the experiment. The results showed that K(trans) of CWR22-cas tumors 36±4 days after ADT was 47.1% higher than K(trans) of CWR22 tumors (P = .01). CWR22-cas tumors showed no significant changes in K(trans) after radiation, whereas K(trans) of CWR22 tumors at day 1 decreased compared with pretreatment values (P = .04) before a continuous increase from day 1 to day 9 followed (P = .01). Total PSA in blood correlated positively to tumor volume (r = 0.59, P < .01). In conclusion, androgen-exposed xenografts demonstrated radiation-induced reductions in vascularization and tumor volumes, whereas androgen-deprived xenografts showed increased vascularization and growth inhibition, but no significant additive effect of radiation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20927320      PMCID: PMC2950331          DOI: 10.1593/neo.10484

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  20 in total

1.  Quiescence in R3327-G rat prostate tumors after androgen ablation.

Authors:  A Pollack; D L Joon; C S Wu; C Sikes; M Hasegawa; N H Terry; R A White; G K Zagars; M L Meistrich
Journal:  Cancer Res       Date:  1997-06-15       Impact factor: 12.701

2.  Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI.

Authors:  K Hittmair; G Gomiscek; K Langenberger; M Recht; H Imhof; J Kramer
Journal:  Magn Reson Med       Date:  1994-05       Impact factor: 4.668

3.  CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.

Authors:  M Nagabhushan; C M Miller; T P Pretlow; J M Giaconia; N L Edgehouse; S Schwartz; H J Kung; R W de Vere White; P H Gumerlock; M I Resnick; S B Amini; T G Pretlow
Journal:  Cancer Res       Date:  1996-07-01       Impact factor: 12.701

Review 4.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.

Authors:  M Höckel; P Vaupel
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

Review 5.  Angiogenesis and prostate cancer tumor growth.

Authors:  Brian Nicholson; Dan Theodorescu
Journal:  J Cell Biochem       Date:  2004-01-01       Impact factor: 4.429

6.  Metabolic response of the CWR22 prostate tumor xenograft after 20 Gy of radiation studied by 1H spectroscopic imaging.

Authors:  Jonathan P Dyke; Kristen L Zakian; William M Spees; Cornelia Matei; Yuchen Chen; Xiangling Mao; Dikoma C Shungu; Jason A Koutcher
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

7.  Xenografts of primary human prostatic carcinoma.

Authors:  T G Pretlow; S R Wolman; M A Micale; R J Pelley; E D Kursh; M I Resnick; D R Bodner; J W Jacobberger; C M Delmoro; J M Giaconia
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

8.  Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors.

Authors:  P Westin; P Stattin; J E Damber; A Bergh
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

9.  Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.

Authors:  Gilda G Hillman; Vinita Singh-Gupta; Hao Zhang; Areen K Al-Bashir; Yashwanth Katkuri; Meng Li; Christopher K Yunker; Amit D Patel; Judith Abrams; E Mark Haacke
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

10.  CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.

Authors:  M A Wainstein; F He; D Robinson; H J Kung; S Schwartz; J M Giaconia; N L Edgehouse; T P Pretlow; D R Bodner; E D Kursh
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

View more
  8 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

Review 2.  Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies.

Authors:  James P B O'Connor; Alan Jackson; Geoff J M Parker; Caleb Roberts; Gordon C Jayson
Journal:  Nat Rev Clin Oncol       Date:  2012-02-14       Impact factor: 66.675

3.  Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.

Authors:  Kathrine Røe; Lars Tg Mikalsen; Albert J van der Kogel; Johan Bussink; Heidi Lyng; Anne H Ree; Laure Marignol; Dag R Olsen
Journal:  Radiat Oncol       Date:  2012-05-23       Impact factor: 3.481

4.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

5.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

6.  Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts.

Authors:  Eirik Hagtvet; Kathrine Røe; Dag R Olsen
Journal:  Radiat Oncol       Date:  2011-10-07       Impact factor: 3.481

7.  Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study.

Authors:  Kathrine Røe; Manish Kakar; Therese Seierstad; Anne H Ree; Dag R Olsen
Journal:  Radiat Oncol       Date:  2011-06-08       Impact factor: 3.481

8.  Radiation treatment monitoring using multimodal functional imaging: PET/CT ((18)F-Fluoromisonidazole & (18)F-Fluorocholine) and DCE-US.

Authors:  Natalia Arteaga-Marrero; Cecilie Brekke Rygh; Jose F Mainou-Gomez; Tom C H Adamsen; Nataliya Lutay; Rolf K Reed; Dag R Olsen
Journal:  J Transl Med       Date:  2015-12-18       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.